60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
Key Highlights
- ➤SXTP interim babesiosis data expected October 2026 after minimum 24-patient enrollment
- ➤SXTP estimates up to 380,000 annual U.S. patients and $245 million peak sales
- ➤EXYN customers conduct more than 1,000 autonomous missions monthly across industrial sites
- ➤EXYN Tüprag deployment cut scan time from about 40 minutes to five
- ➤EXYN targets U.S. government and defense programs, including planned Air Force deployment
Expert Statements
Geoff Dow, President and CEO of 60 Degrees Pharmaceuticals
“all three patients with relapsing babesiosis were cured following tafenoquine treatment”
Ben Williams, CEO and COO of Exyn Technologies
“Exyn's field-proven autonomy, high-accuracy mapping and platform-agnostic software position the Company across robotics, digital mapping and autonomous data collection markets.”
ORLANDO, FL / ACCESS Newswire / October 2, 2026 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP; SXTPW) and Exyn Technologies Inc. (Nasdaq:EXYN; EXYNW) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, October 3, at 7:00 p.m. Eastern Time (ET), and on CNBC this Sunday, October 4, at 11:00 a.m. ET. Bloomberg TV is available in an estimated 73 million homes across the United States, and CNBC is available in approximately 90 million U.S. households.
Access the interviews in their entirety at: * SXTP: https://www.redchip.com/assets/access/sxtp_access * EXYN: https://www.redchip.com/assets/access/exyn_access SXTP: Advancing Tafenoquine for Babesiosis Through a Potential Accelerated Regulatory Pathway
Get started
Create a free account to read the full story.